Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
5.50
-0.49 (-8.18%)
Aug 18, 2026, 4:00 PM EST
Silence Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.62 | 0.56 | 43.26 | 31.64 | 21.66 | 16.81 | |
Revenue Growth | -97.74% | -98.71% | 36.71% | 46.12% | 28.82% | 124.73% |
Cost of Revenue | 0.09 | 0.22 | 11.81 | 12.87 | 13.46 | 10.1 |
Gross Profit | 0.53 | 0.34 | 31.45 | 18.78 | 8.19 | 6.71 |
Selling, General & Admin | 21.27 | 22.34 | 26.88 | 26.22 | 25.68 | 27.09 |
Research & Development | 43.68 | 60.29 | 54.15 | 44.99 | 33.73 | 41.66 |
Operating Expenses | 64.95 | 82.63 | 81.03 | 71.21 | 59.41 | 68.75 |
Operating Income | -64.43 | -82.29 | -49.58 | -52.43 | -51.22 | -62.03 |
Interest Expense | - | - | - | - | - | -0.01 |
Interest & Investment Income | 0.02 | 0.02 | 0.7 | - | - | 0.01 |
Currency Exchange Gain (Loss) | 1.58 | -8.47 | 0.65 | -2.64 | 1.29 | -0.06 |
Other Non Operating Income (Expenses) | 2.88 | 3.47 | 3.77 | 1.8 | 0.28 | - |
EBT Excluding Unusual Items | -59.95 | -87.28 | -44.46 | -53.27 | -49.65 | -62.09 |
Merger & Restructuring Charges | - | -1.32 | - | - | - | - |
Pretax Income | -59.95 | -88.6 | -44.46 | -53.27 | -49.65 | -62.09 |
Income Tax Expense | 0 | 0.01 | 0.85 | 0.96 | 0.69 | -8.73 |
Net Income | -59.95 | -88.61 | -45.31 | -54.23 | -50.33 | -53.36 |
Net Income to Common | -59.95 | -88.61 | -45.31 | -54.23 | -50.33 | -53.36 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 47 | 47 | 46 | 37 | 32 | 30 |
Shares Outstanding (Diluted) | 47 | 47 | 46 | 37 | 32 | 30 |
Shares Change | 0.09% | 2.12% | 24.69% | 15.21% | 8.58% | 8.78% |
EPS (Basic) | -1.27 | -1.88 | -0.98 | -1.46 | -1.56 | -1.80 |
EPS (Diluted) | -1.27 | -1.88 | -0.98 | -1.46 | -1.56 | -1.80 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -42.27 | -62.33 | -67.85 | -49.52 | -57.22 | 7.44 |
Free Cash Flow Per Share | -0.90 | -1.32 | -1.47 | -1.33 | -1.78 | 0.25 |
Gross Margin | 85.85% | 61.54% | 72.70% | 59.34% | 37.83% | 39.94% |
Operating Margin | -10475.61% | -14720.93% | -114.62% | -165.70% | -236.53% | -369.02% |
Profit Margin | -9748.45% | -15851.88% | -104.74% | -171.37% | -232.44% | -317.44% |
Free Cash Flow Margin | -6872.52% | -11149.55% | -156.85% | -156.49% | -264.22% | 44.26% |
EBITDA | -63.94 | -81.74 | -48.99 | -51.81 | -50.62 | -61.69 |
EBITDA Margin | - | - | -113.25% | -163.74% | -233.78% | - |
D&A For EBITDA | 0.48 | 0.56 | 0.59 | 0.62 | 0.6 | 0.34 |
EBIT | -64.43 | -82.29 | -49.58 | -52.43 | -51.22 | -62.03 |
EBIT Margin | - | - | -114.62% | -165.70% | -236.53% | - |